Good morning, you're tuned in to Markets Desk.
Kodiak Sciences is the standout mover in biotech today after its drug candidate KSI-five oh one, developed under the Zenkuda program, hit its primary endpoints in a Phase three clinical trial. That's the highest bar in drug development, and clearing it means the company now has a credible path toward regulatory review. Investors responded decisively, sending the stock sharply higher on heavy volume.
Shifting to commodities and their ripple effects, crude oil prices are climbing on renewed geopolitical tension, and that pressure is landing squarely on Indian equities. GIFT Nifty futures are pointing to a flat to slightly negative open in Mumbai, with energy import costs a particular concern for an economy that relies heavily on foreign oil. Weak sentiment across broader Asian markets is compounding the drag.
On the dividend front, Broadcom continues to stand out as one of the most consistent income compounders in the semiconductor space. The company has raised its annual dividend fifteen straight years, and with that payout growing roughly ninety-fold since two thousand ten, investors are already watching for what is typically a December announcement. The most recent raise came in at ten percent.
That's the tape. Markets Desk, signing off the floor.
